Results 11 to 20 of about 175,167 (244)

MicroRNAs in Cardiac Hypertrophy [PDF]

International Journal of Molecular Sciences, 2019
Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac hypertrophy, with age. This remodeling, however, is intensified under stress and pathological conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal cardiac output in times of need; however, chronic cardiac hypertrophy may ...
Nadine Wehbe, Suzanne Nasser, Gianfranco Pintus, Adnan Badran, Ali Eid, Elias Baydoun   +5 more
openaire   +3 more sources

Myoferlin alleviates pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting NLRP3-mediated pyroptosis [PDF]

PeerJ
Myoferlin (MYOF) is a muscle-derived secretory protein. Recent studies have found that MYOF protects against cell damage. However, the role of MYOF in cardiac hypertrophy remains unclear. Increasing evidence suggests that NLRP3 (NOD-like receptor protein
Yang Zhou, Yanxu Liu, Hao Luo, Cong Wen, Yangyang Cui, Linqing Du, Ofe Eugene Kwaku, Lan Li, Lijuan Xiong, Jiankang Zheng, Xuefeng Ding, Xiufeng Shen, Peng Zhou, Houxiang Hu, Rongchuan Yue   +14 more
doaj   +2 more sources

The function of LncRNA-H19 in cardiac hypertrophy

Cell & Bioscience, 2021
Cardiac hypertrophy, characterized by the enlargement of cardiomyocytes, is initially an adaptive response to physiological and pathological stimuli. Decompensated cardiac hypertrophy is related to fibrosis, inflammatory cytokine, maladaptive remodeling,
Wenhua Su, Qian Huo, Hao Wu, Lulin Wang, Xiaoxue Ding, Liwen Liang, Liang Zhou, Yan Zhao, Juhua Dan, Hong Zhang   +9 more
doaj   +1 more source

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis

Frontiers in Pharmacology, 2022
Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical ...
Yan Chen, Yan Chen, Junteng Zhou, Junteng Zhou, Junteng Zhou, Zisong Wei, Yue Cheng, Geer Tian, Yue Quan, Qihang Kong, Wenchao Wu, Xiaojing Liu, Xiaojing Liu   +12 more
doaj   +1 more source

MALAT1 regulates hypertrophy of cardiomyocytes by modulating the miR-181a/HMGB2 pathway

European Journal of Histochemistry, 2022
Noncoding RNAs are important for regulation of cardiac hypertrophy. The function of MALAT1 (a long noncoding mRNA), miR-181a, and HMGB2; their contribution to cardiac hypertrophy; and the regulatory relationship between them during this process remain ...
Feng Chen, Wenfeng Li, Dandan Zhang, Youlin Fu, Wenjin Yuan, Gang Luo, Fuwei Liu, Jun Luo   +7 more
doaj   +1 more source

CAMTA in Cardiac Hypertrophy [PDF]

Cell, 2006
In this issue of Cell, the Calmodulin binding transcription activator 2 (CAMTA2), is shown by Song et al. (2006) to be an indispensable transcription coactivator for cardiac hypertrophy. CAMTA2 is activated by the dissociation of class II histone deacetylase 5 and promotes transcription of genes involved in cardiac hypertrophy through its interaction ...
Schwartz, Robert J., Schneider, Michael D.   +1 more
openaire   +2 more sources

Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways

Disease Models & Mechanisms, 2015
Cardiac hypertrophy is associated with many forms of heart disease, and identifying important modifier genes involved in the pathogenesis of cardiac hypertrophy could lead to the development of new therapeutic strategies. Tomoregulin-1 is a growth factor
Dan Bao, Dan Lu, Ning Liu, Wei Dong, Ying-Dong Lu, Chuan Qin, Lian-Feng Zhang   +6 more
doaj   +1 more source

Maslinic acid protects against pressure overload-induced cardiac hypertrophy in mice

Journal of Pharmacological Sciences, 2018
Cardiac hypertrophy is characterized by myocyte hypertrophy, accumulation of cardiac collagen, and reactivation of fetal genes. Maslinic acid (MA) is a pentacyclic triterpene with abundance in olive fruit skin and possesses a number of pharmacological ...
Yan-Ling Liu, Chun-Yan Kong, Peng Song, Heng Zhou, Xing-Sheng Zhao, Qi-Zhu Tang   +5 more
doaj   +1 more source

Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses

Cardiovascular Therapeutics, 2021
Background. Cardiac hypertrophy is one of the initial disorders of the cardiovascular system and can induce heart failure. Oxidative stress is an important pathophysiological mechanism of cardiac hypertrophy. Wogonin (Wog), an important flavonoid derived
Xiaowen Shi, Bin Zhang, Zhenliang Chu, Bingjiang Han, Xueping Zhang, Ping Huang, Jibo Han   +6 more
doaj   +1 more source

Role of PI3-Kinase in Angiotensin II-Induced Cardiac Hypertrophy: Class I Versus Class III

Frontiers in Pharmacology, 2021
Cardiac hypertrophy is an adaptive response to cardiac overload initially but turns into a decompensated condition chronically, leading to heart failure and sudden cardiac death.
Tiecheng Zhong, Tiecheng Zhong, Zonggui Wang, Sayeman Islam Niloy, Yue Shen, Stephen T. O’Rourke, Chengwen Sun   +6 more
doaj   +1 more source